SRRK Scholar Rock Holding Corporation Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
15:34
Sep 17
Sep 17
r/biotech_stocks
SRRK drug too costly for GLP-1 combo use
The author argues the biggest obstacle for SRRK's drug in muscle wasting alongside GLP-1s is cost: at $310k per year (~$26k/month) versus GLP-1s at $250-$500/month, patients already drop off GLP-1s at the lower price. The mechanism is that payer and patient affordability will prevent adoption alongside GLP-1s unless the price falls substantially. No specific catalyst or timeframe is given; the main risk is that pricing or reimbursement could improve.
SRRK
Scholar Rock Holding Corporation
Short
1ST
—
—
08:48
Sep 15
Sep 15
r/biotech_stocks
SRRK buyout target for LLY or NVO
The author owns SRRK and believes it will be acquired by either LLY or NVO because of its muscle preservation function when used alongside GLP-1 drugs. The mechanism is strategic fit: GLP-1 makers may want to add a muscle-preserving agent to their obesity franchises, making SRRK an attractive acquisition target. No specific catalyst or timeframe is given, and the main risk is that no buyout materializes.
SRRK
Scholar Rock Holding Corporation
Long
1ST
—
—
About SRRK Investor Commentary
Across the available history and selected sources, Buzzberg tracks SRRK (Scholar Rock Holding Corporation) across 3 sources: 1 bullish vs 1 bearish calls from 4 authors. Historical directional balance: 0% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 8 total trade ideas tracked. Past 7 days, before deduplication: 2 other directions. Latest voices: u/Weekly-Barracuda-494, u/Cubyface.